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Abstract 
Purpose: To investigate the anti-angiogenic effect of efavirenz in chick chorioallantoic membrane 
(CAM). 
Methods: Fertile eggs of the domestic fowl (Gallus gallus, variant Domesticus) were used as the in vivo 
vascular test environment. Experimental groups were VEGF, thalidomide (negative control), efavirenz 
(test drug), control 1 (treated with diluent) and control 2 (no treatment). CAM photographs were taken 
using a microscope camera. CAM blood vessels were scored as either “present” or “absent”. 
Results: There was association between treatment drugs and growth of CAM blood vessels (p < 0.05) 
as follows: control 1 – 100 %, control 2 – 67 %,  VEGF -  83 %, thalidomide - 17 %, and efavirenz - 0 % 
(n = 30). Although efavirenz had absolute anti-angiogenicity and presented as a potential anti-cancer 
drug, there was no significant difference between the anti-angiogenicity of efavirenz (100 %) and 
thalidomide (83 %) (F = 1.000, p = 0.341).  
Conclusion: Being a first-line drug in both HAART and combination treatment of HIV-1, efavirenz may 
be responsible for spontaneous resolution of secondary cancers in HIV-infected patients on HAART 
regimen. 
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Kaposi sarcoma is the most common cancer 
seen in patients with acquired immunodeficiency 
syndrome (AIDS). Many researchers have 
documented the regression of HIV-associated 
cancers after antiretroviral therapy (ART) 
administration [1-5]. This has been particularly 
reported for lung cancers [6] in relation to the use 
of “highly active antiretroviral therapy” (HAART). 
HAART is a drug schedule that involves the use 
of Efavirenz [7]. HAART induces tumor 
regression [8] and increases the survival rate 
among HIV patients with pulmonary Kaposi 
sarcoma [9]. HAART regime has therefore 
changed the natural history of HIV/AIDS-related 
cancers [8]. Moreover, it lengthens the time from 
onset of treatment to treatment failure [10]. 
Efavirenz is the most widely used non-nucleoside 
reverse transcriptase inhibitor (NNRTI) [11].  
 
Vascular endothelial growth factor (VEGF) is a 
specific and potent mitogen for endothelial cells 
and its roles in development and pathological 
angiogenesis have been documented [12,13]. It 
promotes cancer proliferation and metastatic 
spread by stimulating growth of new vascular 
networks [14]. The current interest in thalidomide 
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lies in its anti-angiogenic properties [15-17]; it 
antagonizes angiogenic factors such as VEGF 
[18] and Tumor necrosis factor alpha (TNF-a) 
[19,20]. Efavirenz is the most widely used 
NNRTI, and is a first line drug in the 
management of HIV in both adults and children. 
In combination with other anti-retroviral drugs 
[21] it suppresses viral load, thereby increasing 
CD4 count.  Nevertheless, Efavirenz has not 
been adequately studied, even in patients with 
advanced HIV disease (patients with CD4 counts 






The work was carried out at the University of the 
Witwatersrand Medical School, under Ethics 
clearance certificate no. 2008/7/1, and also 
followed the guidelines in the NIH publication no. 
85-23, revised 1985 ("Principles of Laboratory 




Thirty (30) freshly laid, fertile eggs of the New 
Hampshire breed of chicken (Gallus gallus 
variant domesticus) and of the same clutches 
were incubated on the 3rd day of development 
(Hamburger and Hamilton’s stage 21) and used 
as in vivo systems, a vascular test environment  
to study angiogenesis. The embryos were staged 
using the Hamburger and Hamilton staging for 
chick embryos [24]. Effect of the known 
angiogenic drug, VEGF, the anti-angiogenic 
drug, thalidomide, and Efavirenz (anti-retroviral 




Reagents were purchased sterile and equipment 
used were autoclaved. Treatments for all groups 
were given at the same time, on day 3 of 
incubation as follows: The blunt side of the eggs 
were sterilized using cotton wool soaked in 70 % 
ethanol and the respective drugs were 
administered into the air cells through a single 
injection, using needles and syringes. The 
control groups were as follows: VEGF-treated 
group served as the Positive control group. 
These subjects were treated with human 
recombinant VEGF protein (R&D Systems). A 
stock solution of 1 mg in 2 ml diluent was first 
prepared and a single dose of 200 µg /embryo 
was given [25]. Thalidomide was used as the 
negative control drug.  A stock solution of 100 
mg/ml was prepared and a single dose of 20 
mg/embryo was given [26 - 27] Control 1 
embryos were treated with equal volume of the 
diluent (1 ml of 70 % ethanol). Control 2 Embryos 
were not manipulated in any way. The test 
subjects were treated with efavirenz, obtained 
from Sequoia Research Products (Pangbourne, 
UK).  A stock solution of 3 mg/ml was first 
prepared and treatment /embryo was 200 µg 
[10]. Gomez-Sucerquia ascertained that this drug 
has a purity of 98 – 100 % and the solutions are 
stable when tested by high performance liquid 
chromatography (HPLC). With the exception of 
Control 2 subjects, an observation window of 1 x 
2 cm dimension was cut into the egg shells on 
day 5 of treatment. This was done using a 
sterilized flexible metal saw. 
 
 
Figure 1: An illustration of the observation window cut 
in the egg shells 
 
CAM sterility was maintained by instillation of 3 
drops of an antibiotic agent (50 µl Penstrept in 50 
ml chick ringer) into each egg window. Besides 
ensuring sterility, this caused the CAM to sink 
below the egg shell surface, for ease of 
embryonic CAM observation and photography. 
CAM images were captured using a Nikon 
microscope camera. The windows were then 
sealed with sterilized transparent tapes and the 
eggs were re-incubated, until day 15 of treatment 
when CAM images were again taken. Test 
results were scored based on the presence or 




All data were analyzed using Statistical Package 
for Social Sciences (version 21, SPSS Inc, 
Chicago, IL) software program. Fisher exact test 
was used to determine the association between 
treatment drugs and growth of CAM blood 
vessels. One-way analysis of variance (ANOVA) 
was used to compare the anti-angiogenic 
efficacy of the drugs. P < 0.05 was considered 




Mean angiogenic score 
 
In Table 1, the results were expressed as mean 
angiogenic effect (n = 6). All control embryos had 
well-formed CAM blood vessels but the un-
manipulated control subjects (control 2), shown 
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in Figure 2B and Figure 2D, had a 100 % 
angiogenicity (mean angiogenic score of 1). This 
was the highest embryonic viability in the 
experiment. VEGF treatment group (Figure 3) 
had the next high mean angiogenic score of 
0.83.  The manipulated control embryos (Control 
1) in Figure 2A and Figure 2C had a score of 
0.67  
 
Table 1: Fisher's exact test results 
 
Treatment drug CAM blood vessel present 
CAM blood 
vessel absent 
  f   % f   % 
VEGF 5 (31.3) 1 (7.1) 
Thalidomide 1 (6.3) 5 (35.7) 
Efavirenz 0 (0.0) 6 (42.9) 
Control 1 4 (25.0) 2 (14.3) 
Control 2 6 (35.5) 0 (0.0) 




Figure 2: Control embryonic CAM. Normal 
angiogenesis in control embryonic CAMs. C - Control. 
Control 1 (Figure 2A) and Control 2 (Figure 2B) 
showed control embryonic CAMs on day 8 of 




Figure 3: VEGF- treated CAMs. While images A) and 
B) were taken on day 8 of incubation (day 5 of 
treatment); images C) and D) were taken on day 18 of 
incubation (day 15 of treatment). In Figure 3A, arrow 
shows vascular haemorrhage by Day 8 of treatment 
 
There was a significant relationship between 
drugs used and the growth of CAM blood 
vessels. Efavirenz treatment group had 42.9 % 
anti-angiogenicity and 0 % angiogenic effect (n = 
30). This was statistically significant (p = 0.001, 
Fisher's exact test). 
 
Efavirenz suppressed angiogenesis in all 6 
subjects (showing absolute anti-angiogenicity 
and 0% angiogenicity). Thalidomide had mean 
angiogenicity of 0.17 and so, failed as a negative 
control drug in that embryo. 
 
There was no significant difference between the 
anti-angiogenic effect of efavirenz and 
thalidomide. Although efavirenz suppressed both 
blood vessel development (angiogenesis) and 
red blood cell formation (erythropoiesis), our 
work did not measure the anti-erythropoietic 
effect of treatment drugs. 
 
Morphological features of the embryos 
 
Figure 2C and Figure 2D show control 1 and 
control 2 CAMs, respectively, on day 18 of 
treatment. Both control subjects had established 
CAM angiogenesis. 
 
Vascular permeability is characteristic of VEGF, 
which is also known as a permeability factor [15].  
In Figure 3B the arrow, HV showed hyper 
vascularization in VEGF-treated CAM on day 8 of 
treatment that persisted up to day 15 of 
treatment (Figure 3C).  Note the “small caliber” 
blood vessels (arrow labelled SC shows). Figure 
3D show CAM of an embryo that had died for an 
unknown reason; its CAM however had well-
formed blood (see arrow labelled BV). This 
incidence seemed peculiar to the embryo. 
 
When compared to control embryos, there were 
no established vascular network in this treatment 
group. But patches of erythropoietic activities 
were found on CAM surfaces on day 8 of 
treatment, as seen in Figure 4A (labeled E) and 
figure 4B (labeled P). By day 15, figure 4C no 
longer showed angiogenic activity in the CAM but 
instead, had excessive fibrotic tissue reaction. In 
Figure 4D, the embryonic CAM had scanty blood 
islands at the margin of the embryonic CAM (see 
arrows, labeled M). 
 
Efavirenz suppressed both angiogenesis and 
erythropoiesis in all the animals. A rather “quiet” 
CAM was therefore descriptive of this treatment 
group.  The CAM in Figure 5C had exaggerated 
tissue reaction. In Figure 5D, a thin fibrous 
structure was seen on the CAM surface. 
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Figure 4: Thalidomide -treated CAMs. While images 
A) and B) were taken on day 8 of incubation (day 5 of 
treatment), images C) and D) were taken on day 18 of 
incubation (day 15 of treatment) 
 
 
Figure 5: Efavirenz-treated CAMs. While images A) 
and B) were taken on day 8 of incubation (day 5 of 
treatment), images C) and D) were taken on day 18 of 
incubation (day 15 of treatment). No angiogenesis or 




Angiogenesis begins with blood vessels forming 
de novo, from mesenchymal precursor cells 
called angioblasts. Angioblasts differentiate into 
endothelial cells that line primordial blood 
vessels called “blood islands”. Blood islands 
contain progenitor blood cells called 
haematoblasts [2].  Both blood vessels and blood 
cells form from embryonic mesoderm. The blood 
vessels subsequently become organized into a 
primordial vascular network in the embryo [9]. 
 
From the results, the mean angiogenic scores 
showed that 5 out of 6 VEGF- treated embryos 
had well established CAM vessels. While 
vascular growth in the presence of exogenous 
VEGF surpassed that of Control 1(chick 
development with embryonic manipulation), it fell 
short when compared to normal uninterrupted 
embryonic development (as in Control 2). This 
suggests that exogenous VEGF did not 
potentiate the effect of endogenous VEGF in 
chick CAM.  However, treatment with VEGF 
caused vascular permeability and haemorrhage. 
This agrees with the fact that VEGF is also 
known as permeability factor [27]. Vascular 
exudation causing secondary ascites has 
occurred in abdominal cancers because cancer 
cells secreted vascular permeability factor [29]. 
Furthermore, VEGF treatment caused hyper 
vascularization in some subjects (Figure 3B and 
3C. This agrees with the work of Drake et al that 
high levels of exogenous VEGF caused vascular 
defects in a way similar to that seen with 50 % 
reduction in VEGF expression such as in 
heterozygous deletion of the VEGF allele [28]. 
Disorder of VEGF expression therefore causes 
vascular disorganization [4,21].  That is why, 
although VEGF use has been recommended in 
the treatment of ischemia and to reduce 
neurological deficits from stroke, it was found 
that an initial suppression of VEGF activity is 
actually necessary to combat vascular 
permeability and the risk of VEGF-induced 
hemorrhage [30]. 
 
The anti-angiogenic effect of thalidomide 
treatment failed in one embryo (n=6).  Studies of 
human and animal tumours reveal that 
occurrence of angiogenesis is crucial in 
tumorigenesis.  Angiogenesis is regulated by 
both activating and inhibitory growth factors [4]. 
Growth factors such as VEGF, Tumour necrotic 
factor (TNF), Epidermal growth factor (EGF), 
Transforming growth factor (TGF) and 
Angiogenin play key roles in tumorigenesis 
[4,10]. Anti-angiogenic drugs such as thalidomide 
suppress cancer growth and enhance patient 
recovery. It is now known that the resultant 
amelia in neonates who mothers used 
thalidomide during pregnancy was due to 
inhibition of blood vessel growth in the 
developing fetal limb bud [17]. It has been 
documented that thalidomide antagonizes 
angiogenic factors and is thus effective for the 
treatment of human cancers. From our work we 
found that although thalidomide -treated CAMs 
had poor blood vessel network, blood islands 
with red blood cells were seen at the periphery of 
CAM surfaces. Unlike thalidomide, the test drug, 
efavirenz, suppressed both angiogenesis and 
erythropoiesis in all 6 subjects. This is a 
significant finding that can be further explored. 
The 100 % anti-angiogenicity of efavirenz 
presents it as a potential anti-cancer drug. 
Distinct CAM pallor therefore characterized this 
drug treatment group; efavirenz had absolute 
anti-angiogenic effect and so, 0 % angiogenicity. 
It contributed 42.9 % anti-angiogenicity to the 
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experiment (n= 30, F = 9.306, p = 0.0005).  Its 
anti-angiogenic property surpassed that of 
thalidomide (35.7 %). However, when we 
compared the anti-angiogenicity of Efavirenz to 
thalidomide (Table 2), there was no significant 
difference between the anti-angiogenicity of 
Efavirenz and Thalidomide (F = 1.000, p = 0.341, 
Table 3). This is because our work did not 
measure the anti-erythropoietic properties of the 
drugs. 
 








VEGF 0.83 0.41 
Thalidomide 0.17 0.41 
Efavirenz 0 0 
Control 1 0.67 0.52 
Control 2 1 0 
F = 9.306; p = 0.005 
 
Table 3: Anti-angiogenic effects of efavirenz and 
thalidomide 
 
Drug N Mean Standard 
deviation 
Thalidomide 6 .17 .41 
Efavirenz 6 .00 .00 
Total 12 .08 .29 
F = 1.000; p = 0.341 
 
We terminated the experiment on day 15 of 
treatment (day 18 of incubation).  At this time, as 
expected, control CAM blood vessels were still 
well-formed. One VEGF-treated embryo died for 
an unknown reason since its CAM blood vessels 
appeared to be well-formed, 5 subjects in the 
group were still viable, out of which, 3 embryos 
had an unusually strong arterial pulsation from 
hypervascularization.  
 
While one embryo in the thalidomide showed 
proof of life, 5 in the group and all efavirenz-
treated subjects had died from lack of 
oxygenation and nourishment by the end of the 
experiment. Efavirenz CAM had severe pallor 
with embryonic resolution. Furthermore, there 
was CAM tissue thickening. Interruption of 
angiogenesis disrupts development of epithelial 
structures [11] and suppresses growth of solid 
tumours. Studies on inhibitors of the VEGF 
signaling pathway are currently being done to 
innovate on cancer treatment [17]. From our 
findings, there seems to be a promise in the use 
of efavirenz, beyond that of thalidomide, in the 
treatment of life-changing conditions such as 
solid tumors, diabetic retinopathy, and macular 
degeneration. Although both efavirenz and 
thalidomide - treated embryos showed signs of 
inadequate blood supply and nourishment, 
efavirenz having shown significant anti-
angiogenic and also anti-erythropoietic properties 
in chick CAM, has a promising future that that 




The findings of this study on efavirenz indicate 
that it has significant anti-angiogenic effect. 
Being a first-line drug used in both HAART and 
combination treatment for HIV infection, the anti-
erythropoietic and anti-angiogenic properties of 
Efavirenz may be responsible for spontaneous 
resolution of HIV-associated cancers seen in 
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